Journal
BLOOD
Volume 115, Issue 3, Pages 615-625Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-06-227363
Keywords
-
Categories
Funding
- Ministerio de Educacio n y Ciencia, Ministerio de Ciencia e Innovacio n [PI081687, SAF2007-61827]
- Departamento de Salud del Gobierno de Navarra [14/2008]
- ISCIII- RTICC [RD06/0020/0078]
- Fundacio n para la Investigacio nMe dica Aplicada y UTE (Spain)
Ask authors/readers for more resources
Acute myeloid leukemias (AMLs) result from multiple genetic alterations in hematopoietic stem cells. We describe a novel t(12; 18)(p13;q12) involving ETV6 in a patient with AML. The translocation resulted in overexpression of SETBP1 (18q12), located close to the breakpoint. Overexpression of SETBP1 through retroviral insertion has been reported to confer growth advantage in hematopoietic progenitor cells. We show that SETBP1 overexpression protects SET from protease cleavage, increasing the amount of full-length SET protein and leading to the formation of a SETBP1 SET-PP2A complex that results in PP2A inhibition, promoting proliferation of the leukemic cells. The prevalence of SETBP1 overexpression in AML at diagnosis (n=192) was 27.6% and was associated with unfavorable cytogenetic prognostic group, monosomy 7, and EVI1 overexpression (P <.01). Patients with SETBP1 overexpression had a significantly shorter overall survival, and the prognosis impact was remarkably poor in patients older than 60 years in both overall survival (P=.015) and event-free survival (P=.015). In summary, our data show a novel leukemogenic mechanism through SETBP1 overexpression; moreover, multivariate analysis confirms the negative prognostic impact of SETBP1 overexpression in AML, especially in elderly patients, where it could be used as a predictive factor in any future clinical trials with PP2A activators. (Blood. 2010; 115: 615-625)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available